Pharma lobbyists focus on a surprising new target: the FDA
Pharma lobbyists have shifted attention to the FDA as a pivotal battleground, aiming to influence regulatory decisions in a closely watched political context. They argue that framing a regulatory outcome as a win for the current administration could improve the odds of approval or favorable timing.
The strategy involves messaging around efficiency, safety, and patient impact while aligning with political narratives that emphasize rapid access to therapies. Lobbyists say the regulatory climate, public perception, and potential signaling to voters are central to maneuvering approvals.
Observers caution that such lobbying could raise concerns about independence and equitable access, but proponents contend that robust data and transparent processes remain essential to any favorable decision.